- Home
- APLT vs TNXP Comparison
APLT vs TNXP Comparison
Compare APLT & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- TNXP
- Stock Information
- Founded
- APLT 2016
- TNXP 2007
- Country
- APLT United States
- TNXP United States
- Employees
- APLT N/A
- TNXP N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- TNXP Health Care
- Exchange
- APLT Nasdaq
- TNXP Nasdaq
- Market Cap
- APLT 178.6M
- TNXP 197.9M
- IPO Year
- APLT 2019
- TNXP N/A
- Fundamental
- Price
- APLT $0.26
- TNXP $16.08
- Analyst Decision
- APLT Buy
- TNXP Buy
- Analyst Count
- APLT 5
- TNXP 1
- Target Price
- APLT $4.13
- TNXP $70.00
- AVG Volume (30 Days)
- APLT 24.7M
- TNXP 763.5K
- Earning Date
- APLT 11-13-2025
- TNXP 11-10-2025
- Dividend Yield
- APLT N/A
- TNXP N/A
- EPS Growth
- APLT N/A
- TNXP N/A
- EPS
- APLT N/A
- TNXP N/A
- Revenue
- APLT $1,000,000.00
- TNXP $10,299,000.00
- Revenue This Year
- APLT N/A
- TNXP $14.79
- Revenue Next Year
- APLT $5,935.35
- TNXP $933.49
- P/E Ratio
- APLT N/A
- TNXP N/A
- Revenue Growth
- APLT N/A
- TNXP N/A
- 52 Week Low
- APLT $0.22
- TNXP $6.76
- 52 Week High
- APLT $10.48
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- APLT 27.74
- TNXP 36.77
- Support Level
- APLT $0.26
- TNXP $15.63
- Resistance Level
- APLT $0.40
- TNXP $18.25
- Average True Range (ATR)
- APLT 0.12
- TNXP 1.27
- MACD
- APLT -0.07
- TNXP 0.23
- Stochastic Oscillator
- APLT 4.83
- TNXP 25.28
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.